Can Adacolumn® be used in patients with active infections? With latent infections?

Dr. Francisco Fernández

Adacolumn® has been used in patients with active disease, particularly in patients with an intestinal infection with cytomegalovirus detected in colonic mucosa using histological and microbiological techniques. And not only has it not led to a worsening of the infection, but it has even allowed us to control it, without the concomitant use of antivirals, and to control the patient’s underlying inflammatory bowel disease. In latent diseases, for example hepatitis B, patients with hepatitis B virus detectable in blood serology who, as isolated cases, have also been treated with Adacolumn® have not experienced any side effects or unfavourable evolution of the B virus infection as a result of the therapy.

References:

• T. Fukuchi,  H. Nakase, M. Matsuura et al.: Effect of intensive granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis positive for cytomegalovirus. J Crohns Colitis. 2013;7(10):803-11.
• T. Yoshino , H. Nakase, M. Matsuura et al: Effect and Safety of Granulocyte-Monocyte Adsorption Apheresis for Patients with Ulcerative Colitis Positive for Cytomegalovirus in Comparison with Immunosuppressants. Digestion. 2011;84(1):3-9.
• H. Nakase, M. Matsuura, T. Chibam Potential role of granulocyte/monocyte adsorptive apheresis for ulcerative colitis with concomitant CMV infection: authors’ reply., A. Pharma. Therap. 2011;33(4): 497-498.
• G Novelli 1, M Rossi, V Morabito, G Ferretti, R Pretagostini, F Ruberto, F Pugliese, N Guglielmo, P B Berloco , Management of hepatitis C virus infection in liver transplantation with adacolumn apheresis. Transplant Proc. 2012;44(7):1946-52.
• Domènech, E., et al Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective. World journal of gastroenterology, 2021 27(10), 908–918.